Skip to content

Bayer Rejected by US Supreme Court in Bid to End Roundup Suits

  • US High Court declined to hear appeal of $25 million verdict
  • Company may need to boost its litigation-settlement reserve
Bayer Roundup brand weedkiller

Bayer Roundup brand weedkiller

Photographer: Daniel Acker/Bloomberg
Updated on

The US Supreme Court rejected a multibillion-dollar appeal from Bayer AG, refusing to shield the company from potentially tens of thousands of claims that its top-selling Roundup weedkiller causes cancer. Bayer shares tumbled.

The justices, without comment, on Tuesday left intact a $25 million award to Edwin Hardeman, a California man who said decades of exposure to Roundup caused his non-Hodgkin’s lymphoma. Germany-based Bayer argued unsuccessfully that the approval of Roundup’s label by federal regulators meant Hardeman’s suit -- and others like it -- couldn’t go forward.